Drug Transporter (DT) Information

General Information of DT
DT ID DTD0372
Gene Name SLC46A1
Protein Name Proton-coupled folate transporter
Gene ID
113235
UniProt ID
Q96NT5
TCDB ID
2.A.1.50.1
3D Structure

Modelled DT Structure

Method: multi-sequence alignment based machine learning

Detail: Structure Info

Synonyms G21; HCP1; Heme carrier protein 1; PCFT; PCFT/HCP1; SLC46A1; Solute carrier family 46 member 1
DT Family Major Facilitator Superfamily (MFS)
Proton Coupled Folate Transporter/Heme Carrier Protein (PCFT/HCP) Family
Tissue Specificity Expressed in kidney, liver, placenta, smallintestine, spleen, retina and retinal pigment epithelium. Lowerlevels found in colon and testis. Very low levels in brain, lung,stomach, heart and muscle. In intestine, expressed in duodenumwith lower levels in jejunum, ileum, cecum, rectum and segments ofthe colon.
Function This transporter mediates the transport of folate and heme in intestinal. Mediates heme uptake from the gut lumen into duodenal epithelial cells. The iron is then released from heme and may be transported into the bloodstream.
Disease(s) Malignant pleural mesothelioma [ICD-11: 2C26.0]
Peripheral T-cell lymphoma [ICD-11: 2A90.C]
Vitamin deficiency [ICD-11: 5B55-5B7Z]
Endogenous Substrate(s) Folate
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

General Variability Data of This DT (VARIDT 1.0)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            4 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Folic acid
 Approved Drug Info Vitamin deficiency 5B55-5B7Z [1]
Methotrexate
 Approved Drug Info Leukemia 2A60-2B33 [2]
Pemetrexed
 Approved Drug Info Malignant pleural mesothelioma 2C26.0 [3]
Pralatrexate
 Approved Drug Info Breast cancer 2C60-2C6Z [4]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
3-iodothyronamine
9950514
EM Info Identified using HeLa cells-PCFT [5]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:            2 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Methotrexate Approved Drug Info Model organism in vivo (rat) Km = 4.2 microM [2]
Pemetrexed Approved Drug Info Human liver cancer cells (HepG2)-PCFT Km = 0.2 microM [3]
References
1 Characterization of uptake of folates by rat and human blood-brain barrier endothelial cells. Biofactors. 2010 May-Jun;36(3):201-9.
2 Site-specific contribution of proton-coupled folate transporter/haem carrier protein 1 in the intestinal absorption of methotrexate in rats. J Pharm Pharmacol. 2009 Jul;61(7):911-8.
3 The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol. 2008 Sep;74(3):854-62.
4 Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 2012 Aug;15(4):183-210.
5 Identification and characterization of 3-iodothyronamine intracellular transport. Endocrinology. 2009 Apr;150(4):1991-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.